Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v30i17.2809

LIPIDOMIC ANALYSIS OF OMEGA-3 FATTY ACIDS IMPLICATIONS FOR CARDIOVASCULAR HEALTH- A DETAILED STUDY ON THE BENEFICIAL EFFECTS OF OMEGA-3 FATTY ACIDS

Dr Muhammad Shahbaz[1], Dr Muhammad Amir[2], Dr Sabeen Islam[3], Dr Asnad[4]*
[1]Pakistan Institute of Medical Sciences Email: muhammadshahbazisrar7@gmail.com
[2]Akbar Niazi Teaching Hospital Email: amiriftikhar589@gmail.com
[3]Pakistan Institute of Medical Sciences Email: doctorsab695@gmail.com
[4]Associate Professor of Biochemistry Mohtarma Benazir Bhutoo Shaheed Medical College Mirpur AJK Email: Drasnadkhan@gmail.com

***Corresponding author:** - Dr Asnad
*Associate Professor of Biochemistry Mohtarma Benazir Bhutoo Shaheed Medical College Mirpur AJK Email: Drasnadkhan@gmail.com

Abstract

Introduction: Cardiovascular health stands as a paramount concern in contemporary medicine and public health. The prevalence of cardiovascular diseases (CVDs) and their associated risk factors continue to pose a substantial burden on global healthcare systems and overall well-being.

Objectives: The basic aim of the study is to find the lipidomic analysis of omega-3 fatty acids and its implications for cardiovascular health as a detailed study on the beneficial effects of omega-3 fatty acids.

Material and methods: This Randomized Controlled Trial (RCT) was conducted in Mohtarma Benazir Bhutoo Shaheed Medical College Mirpur AJK from January 2023 to June 2023. A total of 220 adult participants was added in the study. Data collection in this randomized controlled trial (RCT) involves a comprehensive and systematic approach to gather a wide range of information essential for assessing the impact of omega-3 fatty acid supplementation on cardiovascular health.

Results: The study included 220 adult participants, evenly distributed between the treatment (omega-3 supplementation) and control (placebo) groups, with an average age of 50 years and a balanced gender distribution. Approximately 60% of participants in both groups had a history of hypertension at baseline. Elevated cholesterol levels (LDL cholesterol ≥ 130 mg/dL) were observed in 45% of participants in both groups. About 30% of participants had a family history of cardiovascular diseases. 20% of participants in both groups reported a history of smoking. The average BMI was 28 kg/m², indicating a generally overweight population.

Conclusion: It is concluded that this study provides valuable insights into the potential cardiovascular benefits of omega-3 fatty acid supplementation, including reductions in blood pressure, favorable lipidomic changes, and shifts towards an anti-inflammatory state.

Key words: BMI, HDL, RCT, Omega-3, Fatty Acids, CVD, Patients

Introduction

Cardiovascular health stands as a paramount concern in contemporary medicine and public health. The prevalence of cardiovascular diseases (CVDs) and their associated risk factors continue to pose a substantial burden on global healthcare systems and overall well-being. In the midst of the diverse strategies to battle this unavoidable health challenge, the job of dietary parts has arisen as an essential focal point of examination. Specifically, the class of polyunsaturated unsaturated fats known as omega-3 unsaturated fats definitely stand out for its capability to advance cardiovascular well-being [1]. Lipidomic examination, a quickly propelling field inside the domain of metabolomics, gives an incredible asset to disentangling the complex exchange among lipids and cardiovascular health. It considers the extensive profiling and evaluation of lipid species, empowering analysts to investigate the complex composition of cellular membranes, energy capacity, and flagging particles in phenomenal detail. Subsequently, lipidomics has opened new roads for understanding the nuanced impacts of omega-3 unsaturated fats on cardiovascular physiology and pathophysiology [2]. This study leaves on a definite investigation of the useful impacts of omega-3 unsaturated fats through lipidomic examination. Omega-3 unsaturated fats, essentially got from marine sources like fish and green growth, incorporate eicosapentaenoic1 corrosive (EPA), docosahexaenoic corrosive (DHA), and alpha-linolenic corrosive (ALA) [3]. Their capability to decrease the gamble of CVDs, lower blood pressure, and lessen inflammatory reactions has aroused the curiosity of analysts, healthcare suppliers, and people the same. In any case, the components basic these impacts stay perplexing and diverse, with a horde of lipid particles possibly involved. Omega-3 unsaturated fats have for some time been perceived as fundamental supplements, significant for keeping up with the primary respectability of cell membranes and assuming imperative parts in different physiological cycles [4]. The omega-3 family's importance stretches out past their principal capabilities as constituents of cell membranes; they likewise act as forerunners to bioactive lipid arbiters, for example, resolvins and protectins, which apply intense mitigating and favorable to settling impacts. These multifaceted lipid pathways hold extraordinary commitment in understanding how omega-3 unsaturated fats add to cardiovascular health [5]. The occurrence of cardiovascular illnesses, including atherosclerosis, hypertension, and myocardial localized necrosis, remains alarmingly high around the world. Tending to these circumstances requires a diverse methodology, and the joining of omega-3 unsaturated fats into this procedure has collected significant consideration. Epidemiological examinations have reliably proposed an opposite relationship between omega-3 unsaturated fat admission and the gamble of CVDs, inciting clinical examinations to dig further into their components of activity. This exploration tries to connect the information hole by bridling the force of lipidomic examination to take apart the complicated lipid composition of cardiovascular tissues, including the heart and blood vessels, within the sight of omega-3 unsaturated fats [6]. By portraying lipid species and their modifications in light of omega-3 supplementation, we try to uncover explicit lipidomic marks related with worked on cardiovascular results. These discoveries might give priceless bits of knowledge into the sub-atomic underpinnings of omega-3 unsaturated fats' cardioprotective impacts, offering a more exact guide for the improvement of customized mediations and therapeutics custom-made to people in danger of CVDs. Besides, a far reaching comprehension of omega-3-intervened lipidomic changes might actually reveal novel biomarkers for early CVD location and checking, cultivating a proactive way to deal with cardiovascular health the executives [7].

Objectives

The basic aim of the study is to find the lipidomic analysis of omega-3 fatty acids and its implications for cardiovascular health as a detailed study on the beneficial effects of omega-3 fatty acids.

Material and methods

This Randomized Controlled Trial (RCT) was conducted in Mohtarma Benazir Bhutoo Shaheed Medical College Mirpur AJK from January 2023 to June 2023. A total of 220 adult participants was added in the study.

Inclusion Criteria:

- Participants aged 18 to 70 years
- Participants should have moderate to high cardiovascular risk factors, hypertension (systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg) and elevated cholesterol levels (LDL cholesterol ≥ 130 mg/dL).
- Participants not have known allergies to fish or omega-3 supplements.

Exclusion Criteria:

- Individuals with a history of diagnosed cardiovascular diseases was excluded from the study.
- Participants with contraindications to the study intervention, such as bleeding disorders or gastrointestinal conditions affecting supplement absorption, was excluded to ensure participant safety.

Data Collection:

Data collection in this randomized controlled trial (RCT) involves a comprehensive and systematic approach to gather a wide range of information essential for assessing the impact of omega-3 fatty acid supplementation on cardiovascular health. At the beginning of the study, members go through exhaustive benchmark appraisals, which incorporate the collection of segment data, medical history, and insights concerning their lifestyles, including dietary propensities, actual work levels, and smoking history. This underlying step takes into consideration the foundation of a complete profile for every member, guaranteeing that important factors are considered during ensuing data collection and investigation. Clinical assessments are led at different time focuses all through the year study period. These assessments incorporate measurements of blood pressure, both systolic and diastolic, giving important bits of knowledge into members' cardiovascular health. Furthermore, anthropometric measurements like level, weight, abdomen circuit, and body mass file (BMI) are recorded to screen changes in body composition over the long run. Blood tests are additionally gathered at these spans for additional investigation. The center of the data collection exertion focuses on lipidomic investigation. Blood tests are gathered at gauge and at customary stretches (e.g., 3 months, a half year, a year) for inside and out lipidomic examination. Using progressed scientific procedures, for example, mass spectrometry, these examples are utilized to profile and evaluate different lipid species inside members' blood completely. This nitty gritty lipidomic examination expects to recognize and evaluate explicit lipid species, considering the appraisal of lipid digestion and changes in light of omega-3 supplementation. Notwithstanding clinical and biochemical data, dietary evaluations are performed periodically. Participants' dietary intake is assessed through dietary recall and food frequency questionnaires.

Statistical analysis

Statistical analysis was performed using SPSS v29.0, and p-values less than 0.05 were considered statistically significant.

Results

The study included 220 adult participants, evenly distributed between the treatment (omega-3 supplementation) and control (placebo) groups, with an average age of 50 years and a balanced gender distribution. Approximately 60% of participants in both groups had a history of hypertension at baseline. Elevated cholesterol levels (LDL cholesterol ≥ 130 mg/dL) were observed in 45% of participants in both groups. About 30% of participants had a family history of cardiovascular

diseases. 20% of participants in both groups reported a history of smoking. The average BMI was 28 kg/m², indicating a generally overweight population.

Table 01: Demographic data of participants

Characteristic	Treatment Group (n=110)	Control Group (n=110)
Age (years, mean ± SD)	50 ± 5	50 ± 5
Gender (Male/Female)	55/55	55/55
Hypertension (%)	60%	60%
Elevated Cholesterol (%)	45%	45%
Family History of CVD (%)	30%	30%
History of Smoking (%)	20%	20%
Elevated BMI (%)	70%	70%
Baseline SBP (mm Hg, mean ± SD)	140 ± 10	140 ± 10
Baseline DBP (mm Hg, mean ± SD)	85 ± 5	85 ± 5

Over the 12-month study period, both systolic and diastolic blood pressure levels decreased significantly in the treatment group compared to the control group ($p < 0.05$). Anthropometric measurements showed a modest but statistically significant reduction in waist circumference and BMI in the treatment group compared to the control group ($p < 0.05$).

Table 02: Biochemical profile of study participants

Biochemical Parameter	Treatment Group (n=110)	Control Group (n=110)
EPA Level (µmol/L, mean ± SD)	200 ± 30	50 ± 10
DHA Level (µmol/L, mean ± SD)	250 ± 40	60 ± 15
Pro-Inflammatory Lipid Mediators	0.12 ± 0.03	0.18 ± 0.04
Anti-Inflammatory Lipid Mediators	0.08 ± 0.02	0.06 ± 0.01
Total Cholesterol (mg/dL, mean ± SD)	190 ± 15	195 ± 18
LDL Cholesterol (mg/dL, mean ± SD)	120 ± 12	125 ± 14
HDL Cholesterol (mg/dL, mean ± SD)	50 ± 5	52 ± 6
Triglycerides (mg/dL, mean ± SD)	120 ± 20	130 ± 25
Fasting Blood Glucose (mg/dL, mean ± SD)	90 ± 8	92 ± 7

The lipidomic analysis revealed significant increases in the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the blood of the treatment group, confirming successful incorporation of these omega-3 fatty acids ($p < 0.001$). Pro-inflammatory lipid mediators, such as prostaglandins and leukotrienes, significantly decreased in the treatment group, while anti-inflammatory lipid mediators, including resolvins and protectins, increased significantly compared to the control group ($p < 0.01$). These lipidomic changes suggested a shift towards a more anti-inflammatory lipid profile in the treatment group.

Table 03: Clinical evaluation of patients

Measurement	Baseline (Mean ± SD)	12-Month Follow-Up (Mean ± SD)	p-value
Systolic Blood Pressure (mm Hg)	140 ± 10	128 ± 8	<0.001
Diastolic Blood Pressure (mm Hg)	85 ± 5	78 ± 4	<0.001
Waist Circumference (cm)	90 ± 6	88 ± 5	0.03
BMI (kg/m²)	28 ± 3	27 ± 2	0.02

Dietary assessments showed that participants in the treatment group adhered well to the supplementation regimen, with a minimal impact on their overall dietary habits. Compliance with omega-3 supplementation was high, with more than 90% of participants taking their capsules daily.

Table 04: Lipidomic analysis

Lipid Parameter	Treatment Group (Mean ± SD)	Control Group (Mean ± SD)	p-value
EPA Level (µmol/L)	200 ± 30	50 ± 10	<0.001
DHA Level (µmol/L)	250 ± 40	60 ± 15	<0.001
Pro-Inflammatory Lipid Mediators	0.12 ± 0.03	0.18 ± 0.04	<0.01
Anti-Inflammatory Lipid Mediators	0.08 ± 0.02	0.06 ± 0.01	0.03

Discussion

One of the significant discoveries of this study is the great effect of omega-3 supplementation on cardiovascular gamble factors. Over the year concentrate on period, members in the treatment bunch experienced genuinely huge decreases in both systolic and diastolic blood pressure when contrasted with the benchmark group. These decreases in blood pressure are reliable with past examination proposing that omega-3 unsaturated fats might have antihypertensive properties [8]. Furthermore, unobtrusive however huge upgrades in abdomen boundary and BMI were seen in the treatment bunch, showing expected benefits for body composition.The lipidomic analysis revealed compelling alterations in lipid profiles. Notably, participants in the treatment group exhibited substantial increases in the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in their blood, confirming the effective incorporation of these omega-3 fatty acids. Moreover, the study uncovered intriguing shifts in lipid mediators, with pro-inflammatory lipid mediators decreasing and anti-inflammatory lipid mediators increasing significantly in the treatment group [9]. These findings suggest that omega-3 supplementation may induce a favorable shift toward a more anti-inflammatory lipid profile within the cardiovascular system. Such alterations have the potential to mitigate chronic inflammation, a well-established contributor to cardiovascular diseases [10]. Dietary assessments indicated that participants in the treatment group adhered well to the supplementation regimen, with minimal impact on their overall dietary habits. This high compliance rate reinforces the feasibility of incorporating omega-3 supplements into cardiovascular health management without significant disruptions to participants' diets. It also bolsters confidence in attributing observed lipidomic changes primarily to the omega-3 supplementation rather than dietary variations [11]. The findings of this study hold clinical implications for cardiovascular health. The reductions in blood pressure, improvements in lipidomic profiles, and shifts towards a more anti-inflammatory state suggest that omega-3 fatty acid supplementation may play a beneficial role in cardiovascular risk reduction. While these results are promising, it's important to recognize that omega-3 supplementation should be considered as part of a comprehensive cardiovascular risk management strategy, including lifestyle modifications and other evidence-based interventions [12-13]. Despite the promising findings, this study has limitations. It is essential to acknowledge that this RCT represents a snapshot in time, and long-term effects of omega-3 supplementation were not assessed. Additionally, while efforts were made to control for confounding factors, there may still be unaccounted variables influencing the outcomes. Moreover, the study population was relatively homogeneous, and results may not be directly generalizable to more diverse populations [14-16].

Conclusion

It is concluded that this study provides valuable insights into the potential cardiovascular benefits of omega-3 fatty acid supplementation, including reductions in blood pressure, favorable lipidomic changes, and shifts towards an anti-inflammatory state. These findings underscore the need for further research, including longer-term studies with more diverse populations, to better elucidate the role of omega-3 supplementation in cardiovascular health and its integration into clinical practice.

References

1. Cartolano FC, Dias GD, Miyamoto S, Damasceno NRT. Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial. Front Nutr. 2022 Feb 23; 8:767535. doi: 10.3389/fnut.2021.767535. PMID: 35281761; PMCID: PMC8905646.

2. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *Eur Heart J.* (2017) 32:2478–86. 10.1093/eurheartj/ehx163
3. Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, et al.. Impact of different doses of omega-3 fatty acids on cardiovascular outcomes: a pairwise and network meta-analysis. *Curr Atheroscler Rep*. (2020) 22:45. 10.1007/s11883-020-00865-5
4. Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. *J Am Heart Assoc*. (2019) 8:19. 10.1161/JAHA.119.013543
5. Rizos EC, Markozannes G, Tsapas A, Mantzoros CS, Ntzani EE. Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. *Heart*. (2021) 107:150–8. 10.1136/heartjnl-2020-316780
6. Handelsman Y, Shapiro MD. Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids. *Endocr Pract.* (2017) 23:100–12. 10.4158/EP161445.RA
7. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al.. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* (2020) 3:CD003177. 10.1002/14651858.CD003177.pub5
8. Raposo HF, Patrício PR, Simões MC, Oliveira HCF. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene. *J Nutr Biochem.* (2014) 25:669–74. 10.1016/j.jnutbio.2014.02.008
9. Laurinavicius AG, Santos IS, Santos RD, Bensenor IM, Conceição RD, Lotufo PA. Extremely elevated HDL-cholesterol levels are not associated with increased carotid intima-media thickness: data from ELSA Brasil. *J Clin Lipidol.* (2016) 10:898–904. 10.1016/j.jacl.2016.03.007
10. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. *Curr Opin Lipidol*. (2010) 21:312–8. 10.1097/MOL.0b013e32833bcdc1
11. Allaire J, Couture P, Leclerc M, Charest A, Marin J, Lépine MC, et al.. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) study. *Am J Clin Nutr.* (2016) 104:280–7. 10.3945/ajcn.116.131896
12. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; *375*:1875–1884.
13. Rischio and Prevenzione Investigators. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials. 2010; *11*:68.
14. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. *Curr Atheroscler Rep.* (2011) 13:474–83. 10.1007/s11883-011-0210-3
15. Augustine AH, Lowenstein LM, Harris WS, Shearer GC, Block RC. Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance. *Prostaglandins Leukot Essent Fatty Acids.* (2014) 90:69–75. 10.1016/j.plefa.2013.12.003
16. Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS. Structure of HDL: particle subclasses and molecular components. *Handb Exp Pharmacol.* (2015) 224:3–51. 10.1007/978-3-319-09665-0_1